[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hong Kong Baptist University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":299},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,71,101,128,151,177,203,232,255,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100643834","phase-2-linzhi-jianghuang-fufang-huoxue-anshen-capsule-for-non-alcoholic-fatty-liver-100643834",false,"NCT07637006","Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver","The Efficacy and Safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver: a Randomized, Double-blinded, Placebo-controlled Trial","LJF","Inclusion Criteria:\n\n* 1\\) Age between 18 and 65 years (inclusive);\n* 2\\) Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) ≥ 10%;\n* 3\\) Liver stiffness measured by transient elastography \\\u003C 7.3 kPa;\n* 4\\) Presence of one or more metabolic risk factors: a. Fasting plasma glucose ≥ 6.1 mmol\u002FL, or 2-hour postprandial glucose ≥ 7.8 mmol\u002FL, or HbA1c ≥ 5.7%, or a history of type 2 diabetes, or HOMA-IR ≥ 2.5; b. Arterial blood pressure ≥ 130\u002F85 mmHg, or receiving antihypertensive medication; c. Fasting serum triglycerides ≥ 1.7 mmol\u002FL;\n* 5\\) Diagnosis of NAFLD with Phlegm-Stasis Obstructing Collateral pattern according to Traditional Chinese Medicine (TCM) criteria, formulated based on the \"Consensus Opinion on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease (2017)\": Primary Symptoms: a. Intercostal stabbing or dull pain; b. Palpable abdominal mass (hypochondriac mass); c. Dark or dull complexion; d. Obesity. Secondary Symptoms: a. Epigastric and chest fullness and oppression; b. Expectoration of sputum; c. Poor appetite and aversion to greasy food; d. Heavy sensation in the limbs. Tongue and Pulse: Dark red tongue with ecchymosis, enlarged tongue body with teeth marks, greasy coating; wiry, slippery, or hesitant pulse. Diagnosis can be established with the presence of at least 2 primary symptoms and 1 or 2 secondary symptoms, in conjunction with the tongue and pulse presentation.\n* 6\\) Understand the trial content thoroughly and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Excessive alcohol intake (converted pure alcohol \\> 210 g per week for men, \\> 140 g per week for women), or an Alcohol Use Disorder Identification Test (AUDIT) score ≥ 8;\n* 2\\) Other liver diseases (e.g., alcoholic hepatitis, viral hepatitis, drug-induced liver disease, Wilson's disease, autoimmune liver disease, etc.), or a history of liver transplantation or liver resection;\n* 3\\) Presence of severe concurrent diseases affecting the heart, brain, hematopoietic system, immune system, or kidneys (BUN \\> 1.5 × ULN, Cr \\> ULN);\n* 4\\) Presence of other endocrine system disorders, such as hyperthyroidism, Cushing's syndrome, etc.;\n* 5\\) History of malignancy that has not been in complete remission for more than 5 years;\n* 6\\) Hepatic decompensation (total bilirubin, platelet count, prothrombin time, albumin \\> ULN; ALT or AST \\> 2 × ULN), presence of ascites, varices, or a history of hepatic encephalopathy;\n* 7\\) Poorly controlled severe hypertension, defined as systolic blood pressure ≥ 180 mmHg and\u002For diastolic blood pressure ≥ 110 mmHg;\n* 8\\) Insulin-dependent diabetes mellitus (e.g., type 1 diabetes mellitus, or current use of insulin), or non-insulin-dependent diabetes mellitus with poor glycemic control (HbA1c ≥ 9.5%), or diabetic acute complications, or diabetes with severe chronic complications;\n* 9\\) Use of medications that may cause hepatic steatosis or steatohepatitis (e.g., tamoxifen, amiodarone, glucocorticoids, tetracyclines, methotrexate, valproate, salicylates, estrogens) or potentially hepatotoxic drugs for 2 consecutive weeks or more within the past year;\n* 10\\) Current use or use within the past 3 months of GLP-1 receptor agonists;\n* 11\\) Adjustment of hypoglycemic, antihypertensive, or lipid-lowering medications within the past 3 months (e.g., adding or discontinuing medication, dose change, or irregular use);\n* 12\\) Regular use of hepatoprotective drugs or vitamin E within the past month;\n* 13\\) History of bariatric surgery within the past year, or body weight change \\> 5% within the past 3 months;\n* 14\\) History of surgery within the past month;\n* 15\\) Coagulation abnormalities, or current use of medications or foods with anticoagulant effects (e.g., aspirin, warfarin, Panax notoginseng, safflower, Angelica sinensis, peach kernel, etc.);\n* 16\\) Concomitant psychiatric or psychological disorders, or substance\u002Fdrug abuse;\n* 17\\) Known allergic constitution, or known allergy to any component of LJF;\n* 18\\) Participation in another clinical trial within the past month;\n* 19\\) Contraindications for MRI examination, such as claustrophobia or presence of metallic implants;\n* 20\\) Individuals of childbearing potential (male or female) with fertility plans; pregnant or lactating women.","ALL","18 Years","65 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a randomized, double-blinded, placebo-controlled clinical trial aimed at evaluating the efficacy and safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF) for non-alcoholic fatty liver.",[28],"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)",[30,31,32,33,34],"Non-alcoholic fatty liver","Traditional Chinese medicine","Non-alcoholic fatty liver disease","Metabolic dysfunction-associated fatty liver disease","Linzhi Jianghuang Fufang Huoxue Anshen Capsule","NOT_YET_RECRUITING","2026-06-07",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":22},"2026-09",{"date":43,"type":22},"2029-01",{"name":45,"class":46},"Hong Kong Baptist University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100629036","continuous-music-and-sports-training-for-children-100629036","NCT07469423","Continuous Music and Sports Training for Children","JC Project MuSE: Continuous Music and Sports Training for Primary School Children","Inclusion Criteria:\n\n* Primary two to four students and their parents or guardians at local government schools or aided schools\n* The school has 30% or more of their total student population receiving Comprehensive Social Security Assistance (CSSA) and School Textbook Assistance\n* Have provided informed consent indicating participation in the study\n\nExclusion Criteria:\n\n* Presence of significant physical, psychological, and cognitive comorbidities that will hinder participation in research procedures and the designed interventions of continuous music or sports training.",true,{"count":56,"type":22},620,[58],"NA","The current study, JC Project MuSE, is a multi-year project aimed at initiating transformative changes in the lives of young learners in schools with a lower socio-economic background through the integration of music and sports education. The research project posits that engaging in structured music and sports programmes can lead to significant improvements in educational performance through the enhancement of executive functions. The research further explores the longitudinal effects of continuous music and sports training, examining the impact of these interventions on developing a greater sense of appreciation for these activities in these young learners. This research is a 3-year study that examines theoretical underpinnings, methodological approaches, and the impact of music and sports interventions to empower youth in schools of lower socio-economic background and promote holistic development through the synergistic effects of sports and music education.",[61],"Primary School Students","2026-03-10",{"date":64,"type":39},"2026-03-13",{"date":66,"type":22},"2026-09-01",{"date":68,"type":22},"2029-12-31",{"name":45,"class":46},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":54,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":70},"100624578","school-based-active-play-intervention-to-facilitate-movement-behaviours-and-fundamental-movement-skills-in-primary-school-children-of-bangladesh-100624578","NCT07411456","School-based Active Play Intervention to Facilitate Movement Behaviours and Fundamental Movement Skills in Primary School Children of Bangladesh","RCT","Inclusion Criteria for Study Participants\n\n* Primary school children aged 6-12 years\n* Must be apparently healthy with no medical conditions limiting participation in physical activity.\n* Should not plan to change schools within 6 months to allow consistent follow-up.\n* Must understand basic Bengali or English.\n* Must be Bangladeshi citizens.\n\nExclusion Criteria for Study Participants\n\n* Children who are currently out of school will be excluded.\n* Children under 6 years of age or over 11 years of age will not be included.\n* Children who regularly participate in structured sports activities, such as cricket, football, or any other sports clubs, will be excluded.\n* Children who are athletes or compete in any organised athletic events will not be included in the study.\n* Children who are involved in dance performances or dance-related activities regularly will be excluded.","6 Years","12 Years",{"count":81,"type":22},354,[58],"Background In Bangladesh, many children do not get enough opportunities for active play because safe play spaces are limited, school culture often prioritises academic success over physical activity, and many families have safety concerns about outdoor play. These factors reduce the time children spend being active, despite the fact that active play is known to be crucial for children's healthy growth and development. Active play helps children move more, stay physically fit, and develop important social and emotional skills such as teamwork, confidence, and enjoyment. It also supports motor skill development, which includes basic skills like running, jumping, throwing, and catching. The lack of active play in everyday life suggests a strong need for school based programs that can safely introduce regular, structured, and enjoyable physical activity opportunities for children.\n\nObjective The main objective of this study is to find out whether a school based active play program can help children increase their daily physical activity, reduce the amount of time they spend sitting, and improve their sleep patterns. The study also aims to examine whether the program improves children's fundamental movement skills, such as running, jumping, throwing, and catching.\n\nMethods This study will use a randomised controlled trial design. Randomisation will be at the school level to ensure fairness and reduce bias. This study will test a 12-week school-based AP programme designed to help primary school children in Bangladesh be more active, sit less, sleep better, and improve their basic movement skills. The study will involve eight primary schools, with each school acting as one cluster. Four schools will receive the AP programme and the remaining four will continue their usual routine. About 43 children from each school will join, giving a total sample of around 343 students.\n\nEligibility Criteria Children can take part if they are students at a primary school, healthy, staying in their school for at least six months, able to understand basic Bengali or English, and are Bangladeshi citizens. Children will not be included if they are outside the age range, not attending school, or regularly involved in organised sports, dance, or athletic training. These rules help ensure that the programme is safe and that the comparison between the AP group and the control group is fair.\n\nIntervention Description The AP programme will run twice a week for 60 minutes. Each session will include 30 minutes of free play where children choose their own games and 30 minutes of researcher-led guided play. Activities will help children practise running, jumping, throwing, catching, and other fundamental skills. Weekly themes will keep the sessions enjoyable. Students will earn activity points for being active during sessions, reducing screen time at home, and following healthy sleep routines. Each week, the top three \"Active Champions'' from every school will receive a small reward.\n\nOrientation Sessions Before the programme begins, orientation sessions will be held for parents, teachers, and children. Parents will learn how to support safe play at home, especially when outdoor play is limited due to dengue or safety concerns. They will also receive tips on reducing screen time and encouraging good sleep habits. Teachers will be trained to integrate active breaks, organise movement-friendly classrooms, use outdoor areas safely, and give feedback to students. Children will learn why active play is important and how it can help their health, learning, confidence, and friendships.\n\nData Collection Plan Data will be collected at three time points: before the programme (T1), immediately after 12 weeks (T2), and eight weeks later (T3). Researchers will collect questionnaire responses, measure height, weight and use wrist-worn accelerometers to measure physical activity, sitting time, and sleep. Teachers and parents will help children wear the devices correctly and keep usage records. Fundamental motor skills will be assessed using the (Test of Gross Motor Development) TGMD 3 tool.\n\nData Analysis Researchers will check all data for accuracy and compare results between the AP and control groups. The study will examine changes in PA, sedentary behaviour, sleep patterns, and FMS. It will also explore whether age, gender, or family background affects how children respond to the programme. The results will help determine whether the AP programme is practical for Bangladeshi schools and effective in improving children's movement behaviours and FMS.\n\nExpected Results It is expected that children who participate in the AP program will show clear improvements in PA levels, movement skills, sitting time, and sleep patterns compared with children in the control group. Schools may also learn simple and low-cost ways to support children's activity within limited time and space, making the program valuable beyond the study itself.",[85,86,87,88],"Physical Activities","Sedentary Behaviors","Sleep","Fundamental Movement Skills",[90,91,88,92],"Active Play","Movement Behaviours","Primary School Children","2026-02-08",{"date":95,"type":39},"2026-02-13",{"date":97,"type":22},"2026-05-01",{"date":99,"type":22},"2027-03-30",{"name":45,"class":46},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":54,"sex":109,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100611641","urinary-incontinence-in-older-hong-kong-women-a-cross-sectional-study-100611641","NCT07243223","Urinary Incontinence in Older Hong Kong Women: A Cross-sectional Study","Epidemiological Profiles, Traditional Chinese Medicine Syndrome, and Biomarkers of Urinary Incontinence in Older Hong Kong Women: A Cross-sectional Study","PROMOTE","Diagnostic Criteria:\n\n1\\. Urinary Incontinence (UI)：Urinary incontinence will be diagnosed according to the definition of the International Continence Society (ICS), that is, 'any involuntary leakage of urine'. In addition, participants must have experienced this symptom continuously for at least six months to exclude cases of transient urinary incontinence.\n\n2\\. Stress Urinary Incontinence (SUI)：The clinical diagnosis of SUI will be made with reference to the guidelines of the European Association of Urology (EAU) and the International Continence Society (ICS):\n\n1. Symptoms: Involuntary leakage of urine during activities that increase intra-abdominal pressure, such as physical exertion, laughing, coughing, or walking; urine leakage stops immediately when the activity ceases.\n2. Signs: Positive result on the cough stress test or a positive 1-hour pad test (the procedure will follow the standardized ICS protocol; leakage \\>1g is considered positive).\n3. Pure urge incontinence and mixed urinary incontinence will be excluded. This subtype will be preliminarily identified using the Chinese version of the \"3 Incontinence Questions\" (3IQ): \"During the past three months, in which of the following situations did you most often experience urine leakage? (single choice) A. During physical activities such as coughing, sneezing, lifting, or exercise; B. When you had the urge to urinate or felt the need to empty your bladder but could not reach the toilet in time; C. Without physical activity or urge; D. Equally during physical activity and urgency.\" (Selection of option A) SUI will be finally confirmed by a one-week bladder diary (showing only stress-related leakage) and a positive 1-hour pad test.\n\n3\\. Urge Urinary Incontinence (UUI)：The clinical diagnosis of UUI will follow the guidelines of the European Association of Urology (EAU) and the International Continence Society (ICS):\n\n1. Symptoms: Involuntary leakage of urine accompanied by or immediately preceded by urgency (a sudden, compelling desire to void that is difficult to defer).\n2. Cases of pure stress urinary incontinence and mixed urinary incontinence will be excluded.\n\nThis subtype will be preliminarily identified using the Chinese version of the \"3 Incontinence Questions\" (3IQ): \"During the past three months, in which of the following situations did you most often experience urine leakage? (single choice) A. During physical activities such as coughing, sneezing, lifting, or exercise; B. When you had the urge to urinate or felt the need to empty your bladder but could not reach the toilet in time; C. Without physical activity or urge; D. Equally during physical activity and urgency.\" (Selection of option B) Final confirmation will be based on a one-week bladder diary recorded by the participant (showing only urgency-related leakage).\n\n4\\. Mixed Urinary Incontinence (MUI)：The clinical diagnosis of MUI will follow the guidelines of the European Association of Urology (EAU) and the International Continence Society (ICS):\n\n1. Symptoms: The presence of stress urinary incontinence symptoms, such as involuntary leakage of urine during activities that increase intra-abdominal pressure (e.g., exercise, laughing, coughing, walking), with urine flow ceasing immediately upon stopping the activity; and, at the same time, the presence of urge urinary incontinence symptoms, such as urgency (a sudden, compelling desire to void that is difficult to defer) accompanied by or immediately followed by involuntary leakage of urine.\n2. Signs: Positive result on the cough stress test or a positive 1-hour pad test (the procedure will follow the standardized protocol of the ICS; leakage \\>1g is considered positive).\n3. Cases of pure urge urinary incontinence and pure stress urinary incontinence will be excluded.\n\nThis subtype will be preliminarily identified using the Chinese version of the \"3 Incontinence Questions\" (3IQ): \"During the past three months, in which of the following situations did you most often experience urine leakage? (single choice) A. During physical activities such as coughing, sneezing, lifting, or exercise; B. When you had the urge to urinate or felt the need to empty your bladder but could not reach the toilet in time; C. Without physical activity or urge; D. Equally during physical activity and urgency.\" (Selection of option D) Final confirmation will be based on a one-week bladder diary recorded by the participant (showing both urgency- and stress-related leakage) and a positive 1-hour pad test.\n\n5\\. Inclusion Criteria for Patients with Urinary Incontinence\n\n1. Females aged ≥55 years\n2. Has been living in Hong Kong for one year or more.\n3. Meet the diagnostic criteria for SUI, UUI, or MUI, and the symptoms of urinary incontinence have persisted for at least 6 months.\n4. Able to understand and follow written and verbal instructions in Chinese or English.\n5. Provide informed consent voluntarily after being fully informed\n\n6\\. Exclusion Criteria for Patients with Urinary Incontinence\n\n1. Diagnosed with types of urinary incontinence other than stress, urge, or mixed urinary incontinence, including those secondary to neurological or systemic diseases (such as post-stroke, post-spinal cord injury, multiple sclerosis, Alzheimer's disease, Parkinson's disease, or uncontrolled diabetic peripheral neuropathy), as well as the overflow incontinence.\n2. Active or structural urogenital diseases (such as unrepaired vesicoureteral reflux, congenital urethral malformations, urogenital fistula, urethral diverticulum, or active pelvic malignancies).\n3. Deemed by researchers to be unable to cooperate with assessments due to severe mental or physical illness.\n\n7\\. Eligible Urinary Incontinence Patients for Bio-Sample Collection\n\n1. The first 300 urinary incontinence patients (100 each with SUI, UUI, and MUI) enrolled in the study.\n2. No chronic comorbidities (except for well-controlled hypertension, defined as systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg, and hyperlipidemia), including neurological disorders (central nervous system injury, motor neuron diseases, neurodegenerative diseases), diabetes, connective tissue diseases, psychiatric disorders, severe cardiovascular or cerebrovascular diseases, and severe liver or kidney diseases.\n3. Not using medications that affect urination or gut microbiota (including but not limited to thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, anticholinergics, α- and β-adrenergic blockers, α- and β-adrenergic agonists, diuretic antihypertensives, antihistamines, muscarinic receptor antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors, hormone medications, neurotransmitter-related drugs, gut microbiota modulators, etc.).\n\n8\\. Inclusion Criteria for Healthy Volunteers\n\n1. Female, aged ≥55 years;\n2. Has been living in Hong Kong for one year or more;\n3. Able to understand and follow written and verbal instructions in Chinese or English;\n4. Fully informed and voluntarily signs the informed consent form.\n\n9\\. Exclusion Criteria for Healthy Volunteers\n\n1. Meet the diagnostic criteria for urinary incontinence;\n2. Has a history of involuntary urine leakage, or has sought medical consultation for symptoms related to urinary incontinence;\n3. Has chronic comorbidities (except for well-controlled hypertension, defined as systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg, and hyperlipidemia).\n4. Uses medications that affect urination or gut microbiota (including but not limited to thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, anticholinergics, α- and β-adrenergic blockers, α- and β-adrenergic agonists, diuretic antihypertensives, antihistamines, muscarinic receptor antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors, hormone medications, neurotransmitter-related drugs, and gut microbiota modulators, etc.).\n5. Deemed by researchers to be unable to cooperate with assessments due to severe mental or physical illness.","FEMALE","55 Years",{"count":112,"type":22},1100,"OBSERVATIONAL","This is a prospective, cross-sectional study aim to include 1000 patients with urinary incontinence and 100 healthy controls in Hong Kong. The overall objection is to address the gaps in epidemiological profiles, TCM syndrome differentiation, and biomarkers discovery of urinary incontinence among older women. The specific aims including:\n\n1. To assess the epidemiological characteristics of urinary incontinence among older women, as well as patients' knowledge and healthcare-seeking barriers, and to explore factors influencing the disease subtypes, severity, and healthcare-seeking behaviors;\n2. To establish diagnostic criteria for traditional Chinese medicine (TCM) syndrome differentiation of urinary incontinence, and analyze the distribution of TCM syndromes;\n3. To explore diagnostic biomarkers and severity evaluation biomarkers for three subtypes of urinary incontinence (SUI, UUI, MUI).",[116],"Urinary Incontinence in Old Age",[118,119],"urinary incontinence","female","2025-11-17",{"date":122,"type":39},"2025-11-21",{"date":124,"type":22},"2025-11-30",{"date":126,"type":22},"2027-03-01",{"name":45,"class":46},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":109,"minAge":110,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":70},"100581845","chm-for-female-stress-urinary-incontinence-100581845","NCT06855602","CHM for Female Stress Urinary Incontinence","A Single Arm Pilot Study of the Chinese Herbal Medicine Formula (S-2196) for the Female Stress Urinary Incontinence (SUI)","Inclusion Criteria:\n\n* Females aged ≥55 years\n* Meet the ICUD diagnostic criteria of stress urinary incontinence\n* Measured urine leakage \\>10g in the 1-hour standard pad test\n* Understand and can follow written and verbal instructions in Chinese\n* Able to independently use and complete the electronic diary during the 1-week screening period\n* The subject is informed and voluntarily signs the informed consent form\n\nExclusion Criteria:\n\n* Patients with other types of urinary incontinence, such as neurogenic urinary incontinence, urge urinary incontinence, and overflow urinary incontinence.\n* Subjects with the following urogenital system diseases (vesicoureteral reflux, detrusor instability, congenital urethral abnormalities, urinary tract infection or hematuria indicated by routine urinalysis or urine culture, urogenital fistula, urethral diverticulum, bladder stones, urinary system tumors, abnormal vaginal bleeding, pelvic malignant tumors, uterine prolapse grade II or above).\n* History of SUI surgery or complex urethral surgery, including previous transvaginal tension-free mid-urethral sling, anterior wall prolapse repair, urethral injection therapy, etc.\n* Previous pelvic radiotherapy, radical surgery for pelvic malignant tumors, and pelvic floor surgery.\n* Currently receiving or needing to continue treatment related to urinary incontinence, including pelvic floor muscle training, physical therapy, pessary, and medication.\n* If using medications that affect urination during the screening period (including but not limited to thiazolidinediones, sodium-glucose cotransporter 2 inhibitors, anticholinergics, alpha- and beta-adrenergic receptor antagonists, alpha- and beta-adrenergic receptor agonists, diuretic antihypertensive drugs, antihistamines, M receptor antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors, hormonal drugs, neurotransmitter drugs, intestinal flora regulating drugs, etc.), and unable to maintain a stable dose during the study period; or if considering using the above medications during the study period but not using them during the screening period.\n* Presence of neurological disorders (including but not limited to central nervous system injury, motor neuron disease, neurodegenerative diseases), diabetes, connective tissue diseases, mental disorders, hypertension (defined as long-term monitored systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg), severe cardiovascular and cerebrovascular diseases, severe liver or kidney diseases.\n* Combined with chronic cough diseases such as chronic obstructive pulmonary disease (COPD), gastrointestinal diseases affecting drug absorption, or other chronic diseases in an unstable state.\n* History of adverse reactions to traditional Chinese medicine, or G6PD deficiency.\n* Unable to complete exercises such as walking or climbing stairs.\n* Deemed unsuitable for participation in this study by the researchers due to psychological or physical reasons.",{"count":136,"type":22},15,[58],"This single-arm, open-label pilot clinical trial will test the hypothesis that S-2196, a Chinese herbal medicine formula, will show efficacy and safety in alleviating the amount and frequency of urinary incontinence in female individuals with stress urinary incontinence. All participants (n=15) will receive 1 week of screening, 2 weeks of intervention, and 1 week of follow-up.",[140],"Stress Urinary Incontinence (SUI)",[142,119],"stress urinary incontinence","RECRUITING",{"date":145,"type":39},"2025-11-20",{"date":147,"type":39},"2024-10-21",{"date":149,"type":22},"2026-05-22",{"name":45,"class":46},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":70},"100597260","brief-behavioral-intervention-to-maintain-sleep-regularity-in-young-adults-over-the-christmas-break-100597260","NCT07056179","Brief Behavioral Intervention to Maintain Sleep Regularity in Young Adults Over the Christmas Break","REST Trial: Effects of a Brief Behavioral Intervention to Maintain Sleep Regularity in Young Adults Over the Christmas Break","REST","Inclusion Criteria:\n\n1. Young adults aged 18-24 years;\n2. Will stay in Hong Kong during the study period;\n3. Will not engage in any activities that require a fixed sleep or wake-up time (e.g., work or study during the holiday period) as these activities could regularize the sleep schedule and potentially contaminate the results.\n\nExclusion Criteria:\n\n1. Have been in a different time zone within two weeks before the baseline assessment;\n2. Diagnosed with circadian rhythm disorders such as delayed sleep-wake phase disorder (DSWD), advanced sleep-wake phase disorder (ASWD), irregular sleep-wake rhythm disorder (ISWRD), and non-24-hour sleep-wake rhythm disorder (N24WSD);\n3. Diagnosed with sleep disorders that directly\u002Findirectly interfere with sleep regularity (e.g., insomnia, sleep apnea);\n4. Use of medications or treatment that may influence sleep regularity (e.g., hypnotics, antidepressants);\n5. Diagnosed with serious physical or mental diseases such as cancer, end-stage liver or kidney diseases, schizophrenia, and psychosis.","24 Years",{"count":161,"type":22},236,[58],"This study will employ a randomized controlled trial design to investigate the effects of a brief behavioral intervention that includes (1) self-recording of a regularity-focused sleep diary, (2) 10 strategies for maintaining sleep regularity, and (3) a sleep education information sheet on the maintenance of sleep regularity in young adults during the Christmas break.",[87],[166,167,168],"sleep regularity","brief behavioral intervention","young adults","2025-07-08",{"date":171,"type":39},"2025-07-11",{"date":173,"type":22},"2025-11-01",{"date":175,"type":22},"2026-01-31",{"name":45,"class":46},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":54,"sex":109,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":70},"100584377","effects-of-high-intensity-interval-training-on-bone-health-in-hong-kong-older-women-100584377","NCT06888544","Effects of High-Intensity Interval Training on Bone Health in Hong Kong Older Women","Effects of High-Intensity Interval Training on Bone Health, Physical Fitness and Quality of Life in Elderly Women With Osteopenia: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* • 60 to 74 years at the start date of the project\n\n  * diagnosed with osteopenia by DXA scan screening with a BMD at the femoral neck or total hip or lumbar spine between -1 and -2.5 SD T-score below the average values\n  * Passing the PAR-Q plus screening or with the physician's approval for readiness to participate in high-intensity exercise\n  * Above the average level of 2-mins stepping showing competent aerobic fitness\n  * No restriction on physical mobility\n  * No cognitive impairment, as determined by the Chinese version of the Mini-Mental Status Examination (i.e., score \\\u003C 24)\n  * No previous substantial experiences in practicing HIIT. The written informed consent form will be collected from each participant\n\nExclusion Criteria:\n\n* • Severe chronic disease restricting high-intensity exercise\n\n  * Having cognition impairment regarded by specialists\n  * checked through medical records at HA Go app platform in the past 6 months, have concurrent medical conditions (e.g., thyrotoxicosis or hyperparathyroidism, Paget's disease, renal disease, diabetes, knee or hip osteoarthritis) and use medications (e.g., corticosteroids, estrogen, thyroxine, thiazide diuretics, or antiretroviral agents) known to affect bone metabolism during past 2 years\n  * any condition with osteoporosis, osteoporotic fractures\n  * current smoker\n  * alcohol 3 or more units per day.","60 Years","74 Years",{"count":187,"type":22},48,[58],"Osteoporosis is an age-related disease, characterized by a decreased bone mass and an increased risk of fragility fractures. Osteoporosis leads to increasing mortality, disabilities, morbidity of chronic pain, and the cost of health and social care, as well as decreasing the quality of life from reduced independence and hindered physical, mental, and social well-being.\n\nA recent review and meta-analysis, investigating the association between physical activity and osteoporosis prevention in elderly people, indicated that the traditional exercise interventions (i.e., resistance training) were undertaken for 60+ mins, 2-3 times\u002Fweek for 7+ months. However, participation rates remain low in these exercise programs among older adults, in part due to a need for specialized equipment and correct techniques to prevent injury. In addition, low motivation and associated compliance with such conventional exercise is problematic among older adults.\n\nConsidering there is little evidence of HIIT benefits related to older women with osteopenia, the current study aims to evaluate the effectiveness of a 24-week HIIT intervention on bone mineral density, bone turnover markers and other health-related outcomes among Hong Kong Chinese older women.",[191],"Osteopenia",[191,193,194],"Older women","High-intensity interval training","2025-03-20",{"date":197,"type":39},"2025-03-21",{"date":199,"type":39},"2024-10-16",{"date":201,"type":22},"2026-10-15",{"name":45,"class":46},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":54,"sex":17,"minAge":184,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100573100","a-biopsychosocial-approach-to-improving-multidimensional-frailty-status-in-community-dwelling-older-adults-100573100","NCT06741878","A Biopsychosocial Approach to Improving Multidimensional Frailty Status in Community-Dwelling Older Adults","Inclusion Criteria:\n\n* Age 60 to 80\n* Willing and capable to participate in this study and training\n* Willing and capable to give informed consent to participate in this study\n* Preliminarily classified as physically prefrail\u002Frobust, in that they possess no more than three of the indicators on the Fried Frailty Index (FFI; unintentional weight loss, exhaustion, low physical activity, slow walking speed, weak grip strength; Bieniek et al., 2016)\n* Can walk independently to an elderly centre\n* Have a smartphone for internal group communication and remote interaction with their peers and the instructor\n\nExclusion Criteria:\n\n* History of systematic cardiovascular diseases causing stroke, Parkinson's disease, early stages of Alzheimer's disease, or cognitive impairment\n* Physical injuries or other conditions that would hinder regular attendance and participation in the assessments for the study\n* Concurrent major psychiatric disorder (e.g. major depressive disorder, schizophrenia) or drug and alcohol abuse\n* Unable to handle digital devices\n* Currently undergoing exercise programmes or classified as physically 'very active' (i.e. performing strenuous activity for 5+ hours each week)","80 Years",{"count":211,"type":22},308,[58],"Frailty is a common clinical syndrome that is becoming increasingly important as populations age worldwide. Individuals who are frail are at a higher risk for negative outcomes, such as falls, disability, hospitalizations, and even death. The understanding of frailty has evolved from a straightforward concept to a complex model that includes physical, psychological, cognitive, and social factors. Since frailty is not static and can change over time, early interventions can be beneficial. Nevertheless, research in this area has been challenging due to a lack of agreement on what frailty encompasses and an inadequate understanding of how its different components interact. Defining frailty as a multidimensional issue is essential to recognize the adverse effects that can arise from medical, psychological, and social influences. However, recent studies have not sufficiently addressed how these different aspects work together or developed effective multidimensional interventions.",[215],"Frailty in Older Adults",[217,218,219,220,221,222,223],"Multi-dimensional frailty","Biopsychosocial approach","Exercise training","Nutrition education","Psychosocial support","Older adults","Intervention programs","2024-12-15",{"date":226,"type":39},"2024-12-19",{"date":228,"type":22},"2025-01-01",{"date":230,"type":22},"2026-06-30",{"name":45,"class":46},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":70},"100564783","acupuncture-for-post-covid-19-condition-long-covid-neuropsychiatric-symptoms-100564783","NCT06633666","Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms","Acupuncture for Long COVID Neuropsychiatric Symptoms: a Pragmatic,Randomized Clinical Trial","Inclusion Criteria:\n\n* meet the clinical diagnosis of Long COVID by the World Health Organization (WHO), with no neuropsychiatric symptoms 1 year before infection with Covid-19, and continue to have at least one neuropsychiatric symptom for 2 months after SARS-CoV-2 turned negative 3 months above;\n* aged 12 to 80 years;\n* willing and able to consent, and complete all assessment and study procedures\n\nExclusion Criteria:\n\n* patients with a history of chronic neuropsychiatric symptoms;\n* cardiovascular diseases pre-existing to the Covid-19 episode such as arrhythmia, heart failure, myocardial infarction, and patients with cardiac pacemakers;\n* documented pre-existing history of psychiatric illness, including substance abuse;\n* suicidal tendencies (attempted suicide in the 12 months before the study);\n* any chronic or remote neurological disorder (i.e. stroke, head trauma, epilepsy, tumor);\n* those who participated in other clinical trials within one month;\n* pregnant or lactating female patients;\n* have surgery within two months before the study or will have a scheduled surgery during the study;\n* acute brain injury or acute encephalopathy from another etiology than Covid-19 (e.g., sepsis, liver or renal failure, alcohol or drug withdrawal, drug toxicity);\n* open-heart cardiac surgery or cardiac arrest during the last 6 months;\n* patients who received acupuncture treatment 1 month before the start of the study;\n* patients who were unable to complete the assessment during screening due to severe mental, cognitive, or emotional impairment",{"count":240,"type":22},160,[58],"In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical non-drug treatment.",[244,245,246],"Long Covid19","Neuropsychiatric Symptom","Acupuncture","2024-11-11",{"date":249,"type":39},"2024-11-13",{"date":251,"type":39},"2023-07-30",{"date":253,"type":22},"2026-04-30",{"name":45,"class":46},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":70},"100557198","a-single-arm-pilot-study-of-the-chinese-herbal-medicine-formula-scd-2101-for-the-functional-constipation-in-the-elderly-100557198","NCT06534996","A Single Arm Pilot Study of the Chinese Herbal Medicine Formula (SCD-2101) for the Functional Constipation in the Elderly","Inclusion Criteria:\n\n* (1) Age ≥ 60 years old (2) Meet the Rome IV diagnostic criteria for functional constipation (3) Complete spontaneous bowel movements ≤ 2 times per week, to be assessed based on a 2-week electronic diary record (CSBMs are defined as the number of times within a 24-hour period that the patient can defecate spontaneously without the use of laxatives or enemas and feels that the stool is completely evacuated) (4) Have colonoscopy results with a diagnosis of no significant abnormalities seen or no more than 3 colorectal polyps, each less than 0.5 cm in size (based on results within the last 5 years before screening) (5) Understand and be able to follow written and oral instructions in Chinese (6) Capable of independently using WhatsApp and an electronic diary, and completing a 2-week electronic diary record during the screening period (7) The subject is informed and voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\n* (1) Secondary constipation (constipation caused by drugs or other diseases); (2) Currently using or requiring continued use of medications that may affect the outcomes of the trial (including but not limited to: antibiotics, hormonal drugs, analgesics, neurotransmitter drugs, gut flora-regulating medications, etc.); (3) Colonoscopy or sigmoidoscopy reveals clinically significant abnormalities; (4) Clinically significant abnormalities in laboratory tests or imaging examinations within the last 6 months; (5) History of allergy to traditional Chinese medicine; (6) History of abdominal surgery within the past year (except for laparoscopic appendectomy); (7) Patients with psychiatric diseases or those requiring the use of psychotropic drugs; (8) Deemed by the researchers as unsuitable to participate in this study for psychological or physical reasons.",{"count":262,"type":22},14,[58],"This single-arm, open-label pilot clinical trial will test the hypothesis that SCD-2101, a Chinese herbal medicine formula, will have efficacy in alleviating constipation in elderly individuals with functional constipation. All participants (n=14) will receive 2 weeks of intervention and 2 weeks of follow-up.",[266],"Functional Constipation",[268],"elderly, Chinese Herbal Medicine, Functional Constipation","2024-08-19",{"date":271,"type":39},"2024-08-20",{"date":273,"type":39},"2024-08-01",{"date":275,"type":22},"2024-11-30",{"name":45,"class":46},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":284,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":4},"100550713","chm-for-t2dm--mets-100550713","NCT06450652","CHM for T2DM & MetS","Feasibility, Safety, and Effectiveness of Chinese Herbal Medicine for T2DM Patients With Comorbid Metabolic Syndrome: A Single-arm Pilot Study","Inclusion Criteria:\n\n* Age between 30-75y.\n* Diagnosed with Type 2 diabetes no more than 5 years.\n* Having current prehypertension (systolic blood pressure 130-139 mmHg or diastolic blood pressure 85-89mmHg), or with a history of hypertension (systolic blood pressure 140-159mmHg or diastolic blood pressure 90-99mmHg).\n* Diagnosed with Metabolic Syndrome according to Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) from Chinese Diabetes Society. People who meet 3 of the following diagnostic criteria or more can be diagnosed as Metabolic Syndrome: (a)Abdominal obesity: waist circumference ≥ 90cm for male and ≥ 85cm for female; (b) Hyperglycemia: Fasting blood glucose ≥ 6.1mmol\u002FL or 2-hour postprandial glucose ≥ 7.8mmol\u002FL and\u002For those who have been diagnosed with hyperglycemia and in treatment; (c) Hypertension: blood pressure ≥ 130\u002F85mmHg and\u002For those who have been diagnosed with hypertension and in treatment; (d) Fasting triglyceride ≥ 1.70mmol\u002FL; (e) Fasting HDL-C \\\u003C 1.04mmol\u002FL.\n* Diagnosed with Accumulation of phlegm and dampness pattern or Intertwined phlegm and blood stasis pattern based on Traditional Chinese Medicine (TCM) theory.\n* Stable vital signs and with sufficient sensorimotor and language competency for completing assessments.\n\nExclusion Criteria:\n\n* Allergic history to Chinese herbal drugs or a known allergy to the ingredients of the CHM.\n* Diagnosed with type 1 diabetes, steroid-induced diabetes, gestational diabetes, or specific types of diabetes.\n* Diabetes accompanied by severe complications such as diabetic nephropathy, diabetic ketoacidosis, etc.\n* Secondary obesity (e.g., secondary to pituitary inflammation, tumor, etc.).\n* Secondary hypertension (e.g., pheochromocytoma, renal hypertension, etc.).\n* Secondary hyperlipidemia (e.g., hypothyroidism, nephrotic syndrome, etc.).\n* Experienced at least one day of diarrhea in the past 7 days.\n* With previous stroke history.\n* With unconsciousness, aphasia, and cognitive dysfunction.\n* With severe heart, liver, or kidney disease or bleeding disorders, or with other serious diseases (e.g. cancer, dementia, etc.).\n* Pregnancy or lactation female.\n* Had joined other clinical trial within past 4 weeks.","30 Years","75 Years",{"count":136,"type":22},[58],"This is a single-arm design. A total of 15 Type 2 Diabetes Mellitus (T2DM) patients with comorbid Metabolic Syndrome (MetS) will be recruited from community. The intervention will be a 4-week of Chinese Herbal Medicine granules treatment, which will consist of six Chinese herbs. The primary outcome measure will be fasting plasma glucose and blood pressure. Secondary outcome measures including changes of anthropometric data (body mass index, waist-to-hip ratio), lipid panels (total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein), HbA1C, Framingham Stroke Risk Score (FSRS), Audit of diabetes-dependent quality of Life (ADDQoL), International Physical Activity Questionnaire Short Form (IPAQ-SF), daily step count and physiological parameters from wearable watch, dietary record, retinal and sublingual vein imaging, concurrent medications and adverse events.",[290],"Type 2 Diabetes Mellitus With Metabolic Syndrome","2024-06-05",{"date":293,"type":39},"2024-06-10",{"date":295,"type":22},"2024-06",{"date":297,"type":22},"2024-10",{"name":45,"class":46},""]